Dennis L Winger
CIK 1222645 · Senior Vice President and CFO · last filed 2018-08-21
Dennis L Winger is a Senior Vice President and CFO who has filed 114 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for NKTR, was dated Aug 21, 2018. Across all open-market trades the lifetime net is −$16.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $17.4M across reported positions. 7 SEC filings were submitted jointly with Pacira BioSciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NKTR | Director | 3,183 | $38.65 | $123.0K | -$3.83M | 16 | 2018-08-21 |
| ARAY | Director | 162,181 | $0.13 | $21.7K | $85.9K | 14 | 2017-12-04 |
| PCRX | Director | 7,490 | $36.34 | $272.2K | $250.1K | 5 | 2017-06-16 |
| VRTX | Director | 31,750 | $535.17 | $16.99M | $250.5K | 5 | 2012-03-12 |
| CEPHALON INC (CEPH) Delisted | Director | — | — | — | $0 | 6 | 2011-10-17 |
| CELL GENESYS INC (CEGE) Delisted | Director | 0 | — | — | $0 | 4 | 2009-10-15 |
| APPLIED BIOSYSTEMS INC. (CRA) Delisted | Senior Vice President and CFO | 75,371 | — | — | -$13.04M | 60 | 2008-02-08 |
Recent Filings
114 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-21 | NKTR | Mixed | — | -$1.37M | EDGAR |
| 2018-08-15 | NKTR | Sell (S) | −34,250 | -$2.08M | EDGAR |
| 2018-01-08 | NKTR | Exer (M) | +33,750 | $404.0K | EDGAR |
| 2017-12-04 | ARAY | Grant (A) | +29,126 | $0 | EDGAR |
| 2017-11-17 | ARAY | Tax (F) | −9,505 | -$45.6K | EDGAR |
| 2017-09-21 | NKTR | Grant (A) | +9,000 | $0 | EDGAR |
| 2017-06-16 | PCRX | Grant (A) | +1,357 | $0 | EDGAR |
| 2016-12-02 | ARAY | Grant (A) | +23,762 | $0 | EDGAR |
| 2016-11-22 | ARAY | Tax (F) | −6,818 | -$36.1K | EDGAR |
| 2016-09-23 | NKTR | Grant (A) | +8,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.